June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Yianni Kournoutas: 1st Line Atezolizumab/Bevacizumab vs. Tremelimumab/Durvalumab in Unresectable HCC
Jan 27, 2025, 10:10

Yianni Kournoutas: 1st Line Atezolizumab/Bevacizumab vs. Tremelimumab/Durvalumab in Unresectable HCC

Yianni Kournoutas, Hematologist and Oncologist at Mayo Clinic shared a post on X:

“Great time at GI25, GIASCO so far! Had a blast presenting our study on 1st line atezo/bev vs. treme/durva in unresectable HCC.

Many thanks to my mentors Dr. Tran Nguyen and Dr. Ou for their support and guidance.”

Yianni Kournoutas: 1st Line Atezolizumab/Bevacizumab vs. Tremelimumab/Durvalumab in Unresectable HCC